VB Devices (Vascular Barcelona Devices) joined the Metrix Partners client list in February 2023. The Barcelona company develops medical devices for vascular medicine, starting with peripheral venous disease.

About VB Devices
VB Devices was founded in 2016 by vascular surgeon Dr. Enric Roche together with Federico Grego. Its products come from clinical needs Dr. Roche identified in daily practice, and they are invented and patented by him. According to the company, the goal is to bring standardisation and versatility to vascular procedures.
Its lead product, Purespume, is an automated system for preparing foam used in sclerotherapy, a minimally invasive treatment for varicose veins. Foam sclerotherapy is common, but foam is often prepared by hand, which makes its quality vary between procedures. An automated system aims to produce consistent foam each time, improving reproducibility for physicians.
Why Metrix took on VB Devices
VB Devices is the kind of life sciences project Metrix looks for: a talented team, strong science, a clear drive to succeed and people who are a pleasure to work with. Medical device companies need finance support that understands regulatory timelines and the mix of public and private funding they rely on.
What Metrix provides to medtech clients
- Financial planning that links regulatory and clinical milestones to cash needs.
- Management accounts and reporting for investors and public funders.
- Applications and reporting for non-dilutive funding, such as ENISA, CDTI and EU programmes.
- Fundraising support, from investor materials to due diligence.
- Pricing and reimbursement analysis for target markets.
Five finance lessons for medtech startups
- Regulation drives the cash plan. CE marking under the EU Medical Device Regulation takes time and money. The budget should include notified body fees and clinical evaluation.
- Use public funding early. Spanish and EU programmes can fund development before private investors are ready to commit.
- Know the reimbursement route. Hospitals buy devices when the procedure is reimbursed. Pricing depends on how each health system pays.
- Manufacturing costs matter. Cost of goods at scale determines margin. Early quotes from manufacturers make the model credible.
- Clinician founders are an asset. A surgeon founder brings credibility with users and key opinion leaders.
What medtech founders should prepare before raising
- A regulatory plan with milestones, costs and timelines.
- A summary of patents and freedom-to-operate.
- Unit cost estimates at different production volumes.
- A list of public funding with conditions and repayments.
- A market model by country, based on procedure volumes and reimbursement.
The market for varicose vein treatment
Chronic venous disease affects a large share of adults, and varicose veins are one of the most common reasons for vascular consultations. Treatment has moved from surgery to minimally invasive procedures done in outpatient settings, including thermal ablation and sclerotherapy. Devices that make these procedures simpler, faster or more consistent fit the trend toward treating more patients outside the operating room.
For a device company, this shift means selling to clinics as well as hospitals, with shorter procurement processes but more fragmented customers. Distribution partnerships are often the most efficient route into each country.
Metrix Partners in life sciences
Metrix works with life sciences and medtech companies including DeepUll and Zymvol. Earlier clients include Northern Biologics and Aelix Therapeutics.






